Gut 63:861-863 doi:10.1136/gutjnl-2013-305736
  • PostScript
  • Letter

The insulin-like growth factor 2 (IGF2) mRNA-binding protein p62/IGF2BP2-2 as a promoter of NAFLD and HCC?

Open Access
  1. 1 Department of Pharmacy, Saarland University, Pharmaceutical Biology, Saarbrücken, Saarland, Germany
  2. 2 Institute of Pathology, Medical University of Graz, Graz, Austria
  3. 3 Department of Pathology, Saarland University, Homburg/Saar, Germany
  1. Correspondence to Prof. Alexandra K Kiemer, Department of Pharmacy, Saarland University, Pharmaceutical Biology, P.O. box 15 11 50, Saarbrücken 66041, Germany;{at}
  • Received 23 July 2013
  • Revised 30 August 2013
  • Accepted 4 September 2013
  • Published Online First 30 October 2013

Non-alcoholic fatty liver disease (NAFLD) represents the most common hepatic manifestation of chronic liver diseases in developed countries. Since non-alcoholic steatohepatitis (NASH) is responsible for a large proportion of cryptogenic cirrhosis and cirrhosis represents the main risk factor for hepatocellular carcinoma (HCC), HCC is a severe complication of end-stage NAFLD.1

Recent evidence published in this journal showed the therapeutic potential of an inhibition of the chemokine (C-C motif) ligand 2 (CCL2)/monocyte chemoattractant protein-1 (MCP-1) in NASH.2 The study by Baeck et al elegantly demonstrated that the pharmacological administration of an RNA oligonucleotide against MCP-1 ameliorates murine steatosis and inflammation. Since mice deficient of the MCP-1 receptor also showed attenuated fibrosis, MCP-1 was suggested as a critical link in the axis steatosis–inflammation–fibrosis.2

Here, we report that animals with a liver-specific overexpression of the insulin-like growth factor 2 (IGF2) mRNA-binding protein p62/IMP2-2/IGF2BP2-2 exhibit distinctly elevated Ccl2 expression levels (figure 1A) when fed a methionine–choline-deficient (MCD) diet, which models all hepatic stages of NAFLD. Accordingly, in addition to elevated inflammatory gene expression, p62 transgenics had higher fat deposition (figure 1B) …

Open Access

Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of Gut.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article